Shuttle Pharmaceuticals Holdings, Inc. files regulatory reports that document its clinical-stage pharmaceutical business, Molecule.ai software platform, capital structure and governance. Registration statements and related amendments describe securities offered by the company, risk factors, use-of-proceeds disclosures and security terms, including common stock and pre-funded warrant structures.
Its 8-K reports record material agreements, public-offering activity, preliminary operating results and executive or consulting arrangements. Proxy materials cover annual meeting matters such as director elections, auditor ratification, executive-compensation votes and charter-authority proposals.
Shuttle Pharmaceuticals Holdings, Inc. is calling a virtual special meeting on September 3, 2026 for stockholders of record as of August 5, 2026. Stockholders are asked to approve, for Nasdaq Listing Rule 5635 purposes, large potential issuances of common stock tied to its acquisition of United Dogecoin Inc. and a related Securities Purchase Agreement, including conversions of Series B-1 and Series B-2 Preferred Stock, pre-funded warrants, and common stock purchase warrants.
The meeting also seeks approval to increase shares authorized under the 2018 Equity Incentive Plan to 8,800,000, amend the certificate of incorporation to change the company name to United Compute Inc., and permit possible adjournments. Proposal 1 would allow conversion of Series B-1 Preferred Stock and pre-funded warrants in excess of the 19.99% Exchange Cap, potentially issuing up to approximately 3,800,717 common shares from Series B-1 and pre-funded warrants for an additional 13,783,794 shares, well above the roughly 5,851,290 pre-split shares previously outstanding. The company warns these issuances will dilute existing holders and could pressure the stock price.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported open-market sales of a total of 83,149 shares of Common Stock. The sales on July 13–14, 2026 were executed at $4.67 and $4.48 per share, leaving no directly held shares of this security after the transactions.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported two open-market purchases of common stock. On July 9, 2026 it bought 8,266 shares at $3.38 per share, and on July 10, 2026 it bought 731 shares at $3.11 per share. Following these transactions, HRT Financial LP directly held 61,271 shares of Shuttle Pharmaceuticals common stock.
HRT Financial LP filed an initial ownership report as a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc. (SHPH). The filing lists direct beneficial ownership of 60,540 shares of Common Stock as of the reported date, without reporting any specific buy or sell transaction.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported selling a total of 29,111 shares of common stock in early July. It sold 18,531 shares on July 8 at $3.52 per share and 10,580 shares on July 7 at $3.33 per share in open-market transactions.
After these sales, HRT Financial LP directly holds 52,274 shares of Shuttle Pharmaceuticals common stock. The filing shows straightforward open-market sales with no derivative exercises or related derivative positions reported.
Shuttle Pharmaceuticals Holdings, Inc. reported that significant shareholder HRT Financial LP made offsetting trades in its common stock. On July 2, HRT Financial LP executed an open-market purchase of 7,851 shares at $3.54 per share. On July 6, it executed an open-market sale of 9,022 shares at $3.51 per share, resulting in a modest net reduction of its position. Following these transactions, HRT Financial LP directly held 81,385 shares of Shuttle Pharmaceuticals common stock.
HRT FINANCIAL LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported an open-market purchase of common stock. On July 1, 2026, it bought 3,959 shares of Shuttle common stock at $3.30 per share. After this transaction, HRT FINANCIAL LP directly owns 82,556 shares of Shuttle common stock.
HRT Financial LP, a ten percent owner of Shuttle Pharmaceuticals Holdings, Inc., reported two open-market purchases of common stock. It bought 25,836 shares at $3.44 per share on June 29 and 6,755 shares at $3.23 per share on June 30. After these trades, HRT Financial LP directly holds 78,597 shares of Shuttle Pharmaceuticals common stock.
HRT Financial LP filed an initial ownership report for Shuttle Pharmaceuticals Holdings, Inc. as a ten percent owner. The filing shows direct ownership of 71,842 shares of Common Stock following the reported date. This Form 3 establishes HRT Financial LP’s starting equity position as a large shareholder.
Shuttle Pharmaceuticals Holdings’ wholly owned subsidiary United Dogecoin Inc. is advancing its Dogecoin mining and digital infrastructure strategy. The Company is evaluating proprietary data centre and behind-the-meter power generation opportunities in Idaho and Alberta to support long-term DOGE mining and future AI and high-performance computing workloads.
United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, each delivering 14.4 GH/s, and expects them to be deployed and fully operational within approximately 60 days, subject to delivery and installation. It has also secured a renewable, hydroelectric-powered data centre site providing energy at US$0.064 per kilowatt hour, which is intended to underpin low-cost, scalable mining operations and potential third-party AI hosting services.